BMY Is Rapidly Advancing Its First-Line NSCLC Research Program

Bristol-Myers Squibb (BMY) expects to have a data readout from part two of the CheckMate-227 trial, which evaluates Opdivo-chemotherapy combination in first-line NSCLC patients regardless of PD-L1 expression and tumor histology, in 2019. The company also expects to witness data from the CM-9LA trial, evaluating Opdivo and Yervoy combination regimen concurrently with two cycles of chemotherapy in first-line NSCLC patients in the second half of 2019.